Valneva (NASDAQ:VALN) Sees Strong Trading Volume - Should You Buy?

Key Points

• Valneva's stock experienced a strong trading volume recently, with about 56,288 shares traded, although this marks a 19% decline from the previous session's volume.
• Analysts have a consensus rating of "Buy" with a target price of $15.00, while recent ratings show upgrades and changes from firms like Guggenheim and Jefferies Financial Group.
• Valneva reported better than expected earnings in its latest quarterly results, with a revenue of $54.84 million, exceeding expectations and showing strong performance against analysts' estimates.

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 56,288 shares were traded during trading, a decline of 19% from the previous session's volume of 69,493 shares.The stock last traded at $11.60 and had previously closed at $10.95.

Analyst Ratings Changes

Several research analysts have recently weighed in on VALN shares. Wall Street Zen upgraded Valneva to a "hold" rating in a research note on Saturday, September 6th. Guggenheim cut their price target on Valneva from $14.00 to $13.00 and set a "buy" rating for the company in a research note on Monday, September 8th. Jefferies Financial Group set a $14.00 target price on Valneva and gave the stock a "buy" rating in a research note on Monday, August 25th. Finally, HC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of Valneva in a research note on Monday, August 25th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $15.00.

Valneva Trading Up 4.9%

The company has a current ratio of 2.27, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. The stock has a fifty day moving average of $9.17 and a two-hundred day moving average of $7.36. The company has a market capitalization of $986.91 million, a PE ratio of -11.70 and a beta of 1.78.

Valneva (NASDAQ:VALN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.11. The business had revenue of $54.84 million for the quarter, compared to analysts' expectations of $46.28 million. Valneva had a negative return on equity of 34.78% and a negative net margin of 33.87%. As a group, sell-side analysts anticipate that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Valneva

Large investors have recently made changes to their positions in the business. Marex Group plc bought a new stake in shares of Valneva in the 2nd quarter worth approximately $64,000. GAMMA Investing LLC bought a new stake in shares of Valneva in the 1st quarter worth approximately $94,000. Finally, Frazier Life Sciences Management L.P. bought a new stake in shares of Valneva in the 2nd quarter worth approximately $8,240,000. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.